P

    Prime Medicine, Inc. Common Stock (PRME)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.59
    -0.02 (-0.55%)

    Market Cap: $651.14M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    31%(5/16)
    Avg Surprise
    -19.78%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.23
    Range$-0.28 - $-0.17
    12 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-0.23+0.3%
    60d ago$-0.23+0.5%
    30d ago$-0.23+1.1%
    7d ago$-0.23-1.1%
    Current$-0.23
    Revenue Consensus
    $2M
    Range$0 - $17M
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.20
    Range$-0.37 - $-0.07
    14 analysts
    Revenue Consensus
    $7M
    Range$-2410480 - $49M
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.20---
    Sep 26EST
    		-$-0.23---
    Jun 26
    Reported Aug 6
    		$-0.24$-0.24+0.00%Beat+41.5%
    Mar 26
    Reported May 7
    		$-0.28$-0.25-12.00%Miss+30.0%
    Dec 25
    Reported Mar 3
    		$-0.24$-0.26+6.90%Beat+22.6%
    Sep 25
    Reported Nov 7
    		$-0.32$-0.25-28.00%Miss+27.3%
    Jun 25
    Reported Aug 7
    		$-0.41$-0.36-13.89%Miss+10.9%
    Mar 25
    Reported May 8
    		$-0.40$-0.31-29.03%Miss+9.1%
    Dec 24
    Reported Feb 28
    		$-0.31$-0.49+36.73%Beat+56.9%
    Sep 24
    Reported Nov 12
    		$-0.44$-0.42-4.76%Miss+20.0%
    Jun 24
    Reported Aug 8
    		$-0.46$-0.39-17.95%Miss+2.1%
    Mar 24
    Reported May 10
    		$-0.44$-0.46+4.35%Beat+0.0%
    Dec 23
    Reported Mar 1
    		$-0.72$-0.51-41.18%Miss-28.6%
    Sep 23
    Reported Nov 3
    		$-0.55$-0.46-19.57%Miss+65.8%
    Jun 23
    Reported Aug 7
    		$-0.47$-0.42-11.90%Miss-46.9%
    Mar 23
    Reported May 11
    		$-0.44$-0.41-7.32%Miss-83.3%
    Dec 22
    Reported Mar 9
    		$-0.56$-0.65+13.85%Beat-
    Sep 22
    Reported Oct 21
    		$-1.61$-0.55-192.73%Miss-
    Mar 22
    Reported Jun 29
    		$-0.32$0.00N/AMiss-
    Sep 21
    Reported Dec 20
    		$-0.24$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.32EV/EBITDA-3.10x
    Price/FCF-4.06xFCF Yield-24.65%
    Profitability
    Profit Margin0.00%Operating Margin-3751.00%
    ROE-373.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio3.05xQuick Ratio3.05x
    Trading Statistics
    Beta2.31Avg Volume2.70M
    52-Week High$6.9452-Week Low$2.67

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.46
    SMA 20$3.29
    SMA 50$3.35
    SMA 200$3.54
    EMA 10$3.48
    EMA 20$3.37
    EMA 50$3.31
    EMA 200$3.45

    MACD

    Line: 0.11Signal: 0.05Hist: 0.05

    ADX

    ADX: 19.6+DI: 23.6-DI: 11.6

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down20.0
    PSAR$3.33

    Bollinger Bands

    Upper Band$3.77
    Lower Band$2.80
    %B Position2937%(Upper)
    Band Width0.81

    RSI (14-Day)

    Neutral
    57.0

    Momentum Oscillators

    Stoch %K86.4
    Stoch %D87.8
    Williams %R-16.9
    ROC (10d)13.2%
    Momentum0.42
    CCI (20d)103.7
    MFI (14d)59.8

    Volatility Measures

    ATR (14d)$0.24(6.8%)
    StdDev (20d)0.24
    Hist Vol95.0%(High)

    Volume Flow

    VWAP$3.56
    OBV12.9M
    AD Line-58.6M
    CMF (20d)0.235

    Volume Metrics

    Avg Vol (20d)2.6M
    Vol Ratio0.8x
    VWMA (20d)$3.31

    Pivot Points

    R3$3.93
    R2$3.82
    R1$3.71
    Pivot Point$3.60
    S1$3.49
    S2$3.38
    S3$3.27

    Advanced Oscillators

    TSI10.65
    Ultimate Osc65.2
    KST56.07

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.15M$856,000$838,000$1.23M$1.11M$1.45M$2.18M$209,000$0$591,000$25.69M$0
    Cost of Revenue$0$0$1.88M$0$0$0$1.72M$0$0$0$1.25M$0
    Gross Profit$1.15M$856,000$838,000$1.23M$1.11M$1.45M$2.18M$209,000$0$591,000$-1,247,000$0
    Operating Expenses$44.44M$51.51M$49.45M$55.20M$54.49M$53.85M$46.41M$54.44M$55.67M$48.93M$68.04M$51.46M
    R&D$33.40M$34.10M$34.71M$43.99M$41.38M$40.56M$34.10M$40.34M$43.07M$37.77M$41.46M$40.97M
    SG&A$11.04M$17.41M$14.74M$11.21M$13.12M$13.28M$12.30M$14.10M$12.60M$11.16M$13.08M$10.49M
    Operating Income$-43,285,000$-50,654,000$-48,608,000$-53,973,000$-53,377,000$-52,392,000$-44,222,000$-54,232,000$-55,672,000$-48,341,000$-68,043,000$-51,459,000
    Interest Income$788,000$1.02M$1.08M$1.14M$743,000$1.18M$1.54M$697,000$611,000$676,000$0$410,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-42,109,000$-49,122,000$-46,079,000$-50,582,000$-52,591,000$-51,890,000$-42,276,000$-52,518,000$-55,461,000$-45,627,000$-65,643,000$-50,816,000
    Income Tax Expense$0$0$0$0$0$0$0$0$-134,000$134,000$0$-108,000
    Net Income$-42,109,000$-49,122,000$-46,079,000$-50,582,000$-52,591,000$-51,890,000$-42,276,000$-52,518,000$-55,327,000$-45,761,000$-65,643,000$-50,708,000
    EBITDA$-41,424,000$-48,718,000$-46,074,000$-50,416,000$-51,881,000$-51,536,000$-42,242,000$-52,527,000$-55,938,000$-45,663,000$-67,250,000$-50,907,000
    EBIT$-42,897,000$-50,143,000$-47,162,000$-51,723,000$-53,334,000$-53,072,000$-43,814,000$-53,215,000$-56,072,000$-46,303,000$-67,409,000$-51,226,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PRME

    News

    Prime Medicine (NASDAQ:PRME) Upgraded to Strong-Buy at Chardan Capital

    Chardan Capital has upgraded Prime Medicine (NASDAQ:PRME) to a "strong-buy" rating. Despite the upgrade, the biotechnology company reported a quarterly loss matching estimates but revenue significantly below expectations. Institutional investors and hedge funds, including Alphabet Inc., hold a substantial portion of the company's stock.

    MarketBeat•8/27/26•
    Somewhat-Bullish

    ADAR1 Capital Management LLC Makes New Investment in Prime Medicine, Inc. $PRME

    ADAR1 Capital Management LLC has made a new investment in Prime Medicine, Inc. (NASDAQ:PRME), purchasing over 1.99 million shares valued at approximately $7.37 million. This makes ADAR1 Capital Management LLC a significant institutional holder with 1.10% of Prime Medicine's stock. Other institutional investors like Alphabet Inc., BlackRock Inc., State Street Corp, and Vanguard Group Inc. have also recently acquired or increased their stakes in the biotechnology company.

    MarketBeat•8/26/26•
    Somewhat-Bullish

    Prime Medicine (NASDAQ:PRME) Shares Up 6.3% - Here's What Happened

    Prime Medicine (NASDAQ:PRME) saw its shares increase by 6.3% on Tuesday, closing at $3.4550, though trading volume was significantly lower than average. Despite the stock trading below its average analyst target price of $7.47, analysts generally maintain a "Moderate Buy" rating. The company continues to report losses, with a negative EPS of $0.24 and revenue of $1.15 million in the last quarter, while institutional investors hold 70.37% of its shares.

    MarketBeat•8/25/26•
    Neutral

    Prime Medicine (NASDAQ:PRME) Trading Down 6.9% - Should You Sell?

    Prime Medicine (NASDAQ:PRME) saw its shares drop by 6.9% to approximately $3.30, with a significantly reduced trading volume compared to its average. Despite a consensus "Moderate Buy" rating and an average price target of $7.69 from analysts, the company reported a quarterly loss of $0.24 per share and revenue below estimates. Institutional investors have recently modified their holdings, with some acquiring new stakes and others increasing their positions.

    MarketBeat•8/20/26•
    Bearish

    Prime Medicine (NASDAQ:PRME) Rating Increased to Strong-Buy at BMO Capital Markets

    BMO Capital Markets has upgraded Prime Medicine (NASDAQ:PRME) to a "strong-buy" rating, contributing to a consensus "buy" rating among analysts with a target price of $7.69. The company's shares opened at $3.54, with a market capitalization of $642 million, after reporting a quarterly loss in line with estimates but revenue below expectations. Institutional investors hold a significant 70.37% of the company's stock.

    MarketBeat•8/20/26•
    Bullish

    Frequently Asked Questions About PRME

    Does PRME pay dividends?
    Prime Medicine, Inc. Common Stock (PRME) does not currently pay a regular dividend.
    What is PRME's market cap?
    Prime Medicine, Inc. Common Stock (PRME) has a market capitalization of $651.14M with a current stock price of $3.59.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In